Eduardo García‐Rico

Camilo José Cela University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Ramón A. Álvarez‐Puebla

Universidad Rovira i Virgili

Luca Guerrini

Universidad Rovira i Virgili

Manuel García‐Algar

Universidad Rovira i Virgili

Nicolás Pazos‐Pérez

Universidad Rovira i Virgili

Patricia Gisbert‐Quilis

Universidad Rovira i Virgili

Wolfgang J. Parak

Universität Hamburg

Matteo Masetti

University of Bologna

Judit Morlà‐Folch

Icahn School of Medicine at Mount Sinai

Lisardo Ugidos

Hospital Universitario HM Sanchinarro

Antonio Cubillo

Hospital Universitario HM Sanchinarro

Cooperative Institutions

HM Hospitales

Hospital Universitario HM Sanchinarro

Universidad Rovira i Virgili

Hospital Universitario Príncipe de Asturias

Centro Oncológico de Galicia

Broadcom (Spain)

Universitat de Barcelona

Camilo José Cela University

Hospital Universitario 12 De Octubre

Universidad Complutense de Madrid

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

How to measure faculty clinical activity in a comprenhesive cancer center.

Journal of Clinical Oncology (2017)

Rafael Álvarez-Gallego Jesús Rodríguez-Pascual Lisardo Ugidos Eduardo García‐Rico Cesar Munoz

e18202 Background: The faculty clinical activity in a comprehensive Cancer Center is difficult to measure. Time clinical units is the most common procedure worldwide. In our group we have developed a new system based on the daily real activity of each medical oncologist of our team. Methods: We collected the daily activity from january to december 2016 of each doctor considering different values( from 1 to 4)depending on the complexity of the activity. Follow up visit of a patient (1), treatment visit (2). Clinical trial visit or Inpatient visit (3) and New Patient First visit (4). Then we added all the daily values of each medical oncologist. Results: 2016 Clinical activity growth measured by traditional time methods was consider 31,5%. When we applicated our new method it was 33,4%. The clinical activity of each Oncology Unit changed clearly when we applied our method. For example , breast cancer unit change from 25% to 20 % of the global activity, GI Unit from 47% to 50%, Lung Unit from 13% to 15% . In Genitourinary and Gynecological cancer and Prostate tumor units there are no change. This changes draw the different complexity of each Oncology Unit. It was clearly usefull to get a better information of the real clinical activity of each team and cancer center. Conclusions: This tool can be useful to unifique and compare the different complexity in the clinical activity of Medical Oncology Teams, units and hospitals allocating resources based on this new system.

Clinical Oncology

10.1200/jco.2017.35.15_suppl.e18202

Cite

Citations (0)

Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination

R. Ciérvide Á. Montero Eduardo García‐Rico M. García-Aranda Mercedes Herrero

Primary systemic treatment (PST) downsizes the tumor and improves pathological response. The aim of this study is to analyze the feasibility and tolerance of primary concurrent radio-chemotherapy (PCRT) in breast cancer patients. Patients with localized TN/HER2+ tumors were enrolled in this prospective study. Radiation is delivered concomitantly during the first 3 weeks of chemotherapy, and it is based on a 15 fractions scheme (40.5Gy/2.7Gy per fraction to whole breast and nodal levels I-IV. Chemotherapy is based on Pertuzumab-Trastuzumab-Paclitaxel followed by anthracyclines in HER2+ and CBDCA-Paclitaxel followed by anthracyclines in TN breast cancers patients. 58 patients were enrolled, 25 patients (43%) were TN and 33 patients HER2+ (57%). With a median follow-up of 24.2 months, 56 patients completed PCRT and surgery. A total of 35 patients (87.5%) achieved &gt;90% loss of invasive carcinoma cell in the surgical specimen. The 70.8% and the 53.1% of patients with TN and HER-2+ subtype respectively achieved complete pathological response (pCR). This is the first study of concurrent neoadjuvant treatment in breast cancer in which three strategies are applied simultaneously: fractionation of RT in 15 sessions, adjustment of CT to tumor phenotype and local planning by PET. The pCR rates are encouraging.

Pertuzumab

Chemoradiotherapy

Neoadjuvant Therapy

10.20944/preprints202208.0488.v1

Cite

Citations (3)

The Microbiota in Cancer: A Secondary Player or a Protagonist?

Current Issues in Molecular Biology (2024)

Ana María Gómez García Francisco López‐Muñoz Eduardo García‐Rico

The intestinal microbiota and the human body are in a permanent interaction. There is a symbiotic relationship in which the microbiota plays a vitally important role in the performance of numerous functions, including digestion, metabolism, the development of lymphoid tissue, defensive functions, and other processes. It is a true metabolic organ essential for life and has potential involvement in various pathological states, including cancer and pathologies other than those of a digestive nature. A growing topic of great interest for its implications is the relationship between the microbiota and cancer. Dysbiosis plays a role in oncogenesis, tumor progression, and even the response to cancer treatment. The effect of the microbiota on tumor development goes beyond a local effect having a systemic effect. Another aspect of great interest regarding the intestinal microbiota is its relationship with drugs, modifying their activity. There is increasing evidence that the microbiota influences the therapeutic activity and side effects of antineoplastic drugs and also modulates the response of several tumors to antineoplastic therapy through immunological circuits. These data suggest the manipulation of the microbiota as a possible adjuvant to improve oncological treatment. Is it possible to manipulate the microbiota for therapeutic purposes?

Dysbiosis

Cancer Therapy

10.3390/cimb46080463

Cite

Citations (0)

Optofluidic device for the quantification of circulating tumor cells in breast cancer

Scientific Reports (2017)

Èric Pedrol Manuel García‐Algar J. Massons Moritz Nazarenus Luca Guerrini

Metastatic cancer patients require a continuous monitoring during the sequential treatment cycles to carefully evaluate their disease evolution. Repetition of biopsies is very invasive and not always feasible. Herein, we design and demonstrate a 3D-flow focusing microfluidic device, where all optics are integrated into the chip, for the fluorescence quantification of CTCs in real samples. To test the chip performance, two cell membrane targets, the epithelial cell adhesion molecule, EpCAM, and the receptor tyrosine-protein kinase, HER2, are selected. The efficiency of the platform is demonstrated on cell lines and in a variety of healthy donors and metastatic-breast cancer patients.

Circulating tumor cell

10.1038/s41598-017-04033-9

Cite

Citations (24)

Right hemicolectomy with D2 lymphadenectomy for adenocarcinoma of the colon. Oncological results.

European Journal of Surgical Oncology (2023)

Ana Quiroga‐Valcárcel Fernando Mendoza‐Moreno Belén Matías‐García Yousef Allaoua‐Moussaoui Sonia Soto‐Schütte

Right hemicolectomy

Hemicolectomy

Lymphadenectomy

10.1016/j.ejso.2022.11.382

Cite

Citations (0)

Clinical Diagnostics: Online SERS Quantification of Staphylococcus aureus and the Application to Diagnostics in Human Fluids (Adv. Mater. Technol. 8/2016)

Advanced Materials Technologies (2016)

Carme Catala Bernat Mir-Simón Xiaotong Feng Celia Cardozo Nicolás Pazos‐Pérez

In article number 1600163, Ramon A. Alvarez-Puebla and co-workers combine surface-enhanced Raman scattering encoded particles, biorecognition elements (aptamer/antibody) and microfluidics into a device for the optical detection of Staphylococcus aureus in human fluids. The bacteria quantification is achieved for short acquisition time (10 min mL−1) and at low concentration of S. aureus (<15 CFUs mL−1).

Aptamer

10.1002/admt.201670041

Cite

Citations (1)

Adaptive metabolic pattern biomarker for disease monitoring and staging of lung cancer with liquid biopsy

npj Precision Oncology (2018)

Manuel García‐Algar Ana Fernandez-Carrascal Ana Olano-Daza Luca Guerrini Neus Feliu

In this manuscript, we demonstrate the applicability of a metabolic liquid biopsy for the monitoring and staging of patients with lung cancer. This method provides an unbiased detection strategy to establish a more precise correlation between CTC quantification and the actual burden of disease, therefore improving the accuracy of staging based on current imaging techniques. Also, by applying statistical analysis techniques and probabilistic models to the metabolic status and distribution of peripheral blood mononuclear cell (PBMC) populations "perturbed" by the presence of CTCs, a new category of adaptive metabolic pattern biomarker (AMPB) is described and unambiguously correlated to the different clinical stages of the patients. In fact, this strategy allows for classification of different categories of disease within a single stage (stage IV) before computed tomography (CT) and positron emission tomography (PET) scans and with lower uncertainty.

Liquid biopsy

Imaging biomarker

Circulating tumor cell

10.1038/s41698-018-0059-9

Cite

Citations (6)

Conformational SERS Classification of K‐Ras Point Mutations for Cancer Diagnostics

Angewandte Chemie International Edition (2017)

Judit Morlà‐Folch Patricia Gisbert‐Quilis Matteo Masetti Eduardo García‐Rico Ramón A. Álvarez‐Puebla

Abstract Point mutations in Ras oncogenes are routinely screened for diagnostics and treatment of tumors (especially in colorectal cancer). Here, we develop an optical approach based on direct SERS coupled with chemometrics for the study of the specific conformations that single‐point mutations impose on a relatively large fragment of the K‐Ras gene (141 nucleobases). Results obtained offer the unambiguous classification of different mutations providing a potentially useful insight for diagnostics and treatment of cancer in a sensitive, fast, direct and inexpensive manner.

Molecular diagnostics

Chemometrics

Nucleobase

10.1002/anie.201611243

Cite

Citations (53)

Influence of Healthcare Delivery Type on Patients’ Mental Health: Is Hospitalization Always a Stressful Factor? Can Allostatic Load Help Assess a Patient’s Psychological Disorders?

Clinics and Practice (2024)

Ana María Gómez García Eduardo García‐Rico

Background: Psychological distress is a predictor of future health and disease data, with consequent implications for both the patient and the healthcare system. Taking advantage of the unprecedented situation caused by the COVID-19 pandemic we aimed to assess whether the type of medical care received by patients during the initial months of the pandemic influenced their evolution, particularly at the psychological level. Additionally, we investigated whether allostatic load was associated not only with physical but also psychological alterations. Methods: All the patients diagnosed with COVID-19 infection at HM Madrid Hospital during the month of March 2020 were studied, both those hospitalized (110) and those treated on an outpatient basis (46). They were psychologically evaluated using the Profile of Mood States (POMS) test. We calculated the allostatic load using different laboratory parameters. Results: Outpatient patients had significantly higher scores than hospitalized ones in Tension-Anxiety (52 ± 19.3 vs. 38 ± 4.3; p < 0.001). So, 36.9% of the outpatient patients exhibited anxiety. Allostatic load has not been correlated with patients’ psychological alterations. Conclusions: Psychological distress of outpatient patients should be taken into account in their management to improve mental health planning. This knowledge could provide comprehensive care to patients including their mental health, in the face of subsequent epidemics/pandemics.

Allostatic load

Pandemic

Outpatient clinic

10.3390/clinpract14030079

Cite

Citations (0)

Online SERS Quantification of Staphylococcus aureus and the Application to Diagnostics in Human Fluids

Advanced Materials Technologies (2016)

Carme Catala Bernat Mir-Simón Xiaotong Feng Celia Cardozo Nicolás Pazos‐Pérez

Staphylococcus aureus is a common cause of serious infections. One of the main drawbacks in its treatment is the time required for a positive diagnosis, over 24 h, as most methods are still based in bacterial culture. Herein, a microfluidic optical device for the rapid and ultrasensitive quantification of S. aureus in real human fluids is designed. In this approach, the surface‐enhanced Raman scattering (SERS)‐encoded particles, functionalized with either an antibody or an aptamer, form a dense collection of electromagnetic hot spots on the surface of S. aureus . This allows for an exponentially increase of the SERS signal when particles accumulate on the microorganism as compared to their free condition in bulk solution. Quantification is achieved by passing the sample through a microfluidic device with a collection window where a laser interrogates and classifies each of the induced bacteria–nanoparticle aggregates in real time. Further, the advantages of using aptamers versus antibodies as biorecognition elements are extensively investigated.

Aptamer

10.1002/admt.201600163

Cite

Citations (50)